Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis.

Publication date: Apr 15, 2025

Melanoma brain metastases (MBMs) are diagnosed in up to 60% of metastatic melanoma patients. Previous studies have identified clinical factors that correlate with overall survival (OS) after MBM diagnosis. However, molecular and immune features associated with OS are poorly understood. An improved understanding of the molecular and immune correlates of OS could provide insights into MBM patient outcomes and guide therapeutic development. Thus, we analyzed clinical features and outcomes of 74 melanoma patients who underwent surgical resection (via craniotomy) between 1991 and 2015 at our institution with RNA-seq data generated from their MBMs. The median post-operative OS was 8. 6 months (range 0. 6-146. 9). On univariate analysis (UVA), the expression of multiple immune gene signatures was associated with improved OS, including IFN-γ Index, T cell-inflamed and the Expanded Immune Genes. The gene expression signatures of several immune cell types (i. e., T cells, CD8 T cells, cytotoxic lymphocytes, NK cells, monocytes) positively correlated with OS, whereas higher neutrophil gene expression correlated with shorter OS. UVA of clinical features identified low Karnofsky performance score (KPS), elevated serum lactate dehydrogenase (LDH), presence of extracranial metastases (ECMs), and uncontrolled (versus controlled) ECMs as clinical predictors of shorter survival. Multivariate analyses (MVA) were performed with significant clinical factors and all immune features without any redundant highly correlated variables in the model. After backward selection, multivariable coxPH model identified low KPS, low T cell signature, and low monocytic lineage signature as independent predictors of shorter survival. Finally, comparative analysis of MBMs from patients with MBMs only showed that these tumors were characterized by decreased oxidative phosphorylation (OXPHOS) and increased immune infiltration signature versus MBMs from patients with concurrent ECMs. Together these results support the clinical significance of specific immune features of MBMs and suggest their potential use as prognostic biomarkers.

Open Access PDF

Concepts Keywords
6months Adult
Biomarkers Aged
Dehydrogenase Aged, 80 and over
Tumors Brain Neoplasms
Uncontrolled Female
Humans
Male
Melanoma
Middle Aged
Skin Neoplasms

Semantics

Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH metastasis
disease MESH brain metastases
disease MESH tumors
pathway KEGG Oxidative phosphorylation
disease MESH clinical significance
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Trestolone
pathway REACTOME Reproduction
disease MESH skin cancer
pathway KEGG Metabolic pathways
drug DRUGBANK Dextrose unspecified form
pathway REACTOME Serine biosynthesis
disease MESH noma
drug DRUGBANK Ademetionine
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Sodium Tetradecyl Sulfate
drug DRUGBANK Myricetin
drug DRUGBANK Esomeprazole
disease MESH functional status
disease MESH neuroinflammation
drug DRUGBANK Serine
drug DRUGBANK Glycine
disease MESH tic
disease MESH abnormalities
disease MESH brain edema

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *